Zacks Investment Research is predicting a the bright future ahead for MedTech. An article published on June 15, 2018 states that the suspension of the device tax, a continued M&A “boom,” and myriad economic and geographic factors are leaving the industry feeling very optimistic.
Mark Bonifacio’s thoughts were summarized in article:
“…private equity and strategic OEM (Original equipment manufacturer) buyers are competing for assets in all sectors of medical contract manufacturing and broadening their portfolios or investing in new technologies.
He strongly stated that although the start of 2018 was sluggish with respect to M&As, it was due to uncertainties over changes in the global healthcare market and the fate of Obamacare’s medical device tax. Now that the doubts are gradually getting cleared, the industry is once again heading toward another year of significant M&A activity.”
Take a look at the complete article to gain insight into the factors influencing the industry and learn future projections from Zacks’ independent analysts.
About Zacks Investment Research
Zacks Investment Research is an American company dedicated to the production of independent research and investment-related content. Founded in 1978 by Len Zacks, who armed with his PhD from MIT, hit upon a key discovery: Earnings estimate revisions are the most powerful force impacting stock prices.
The company provides professional investors with financial data and analysis helpful in making better investment decisions for proprietary accounts and the investment accounts of clients. Zacks is probably known best known for their extensive array of consensus earnings-per-share (EPS) estimates. More recently, the company has moved into other related areas including research reports, recommendation summaries on various stocks, stock prices, funds, charts and tables and a host of other investment tools and data.
Zacks Investment Research is used by thousands of analysts at well over 200 brokerages to give clients reliable investment information.